Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3371-3380 Newer>

The Motley Fool December 29, 2006 Brian Lawler	Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide.
The Motley Fool December 29, 2006 Brian Lawler	Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note.
The Motley Fool December 29, 2006 Brian Lawler	InterMune Gets Ready to Sell Shares For investors' sake, getting any necessary dilution over and done with at higher share prices means fewer shares of the diluting financing need to be issued, so it's smart that InterMune is getting ready to sell shares now in case more positive clinical trial results cause shares to spike.
The Motley Fool December 29, 2006 Brian Lawler	SciClone Sees Opportunity in the Far East Pharma SciClone goes about gaining regulatory approval the opposite way from most -- through China. This isn't such a bad idea, considering that drug sales in China grew 20% last year. Investors, take note.
The Motley Fool December 29, 2006 Brian Lawler	Sirna Decides to Take the Cash and Run Shareholders vote to approve Merck's buyout offer. Investors in shares of Merck really have to trust management to have done its due diligence on Sirna and to have faith in its technology.
BusinessWeek January 8, 2007 Catherine Arnst	Decoding Alzheimer's After a century, promising treatments at last - and whispers of a cure.
BusinessWeek January 8, 2007	Diagnosis: Identity Theft For $60, a thief can buy your health records - and use them to get costly care. Guess who gets the bill.
BusinessWeek January 8, 2007 Arlene Weintraub	Is Your Medicine The Real Deal? Accusations are flying that some pharmacies substitute inferior versions of drugs.
BusinessWeek January 8, 2007 Catherine Arnst	Modern Snake Oil? "Natural Causes: Death, Lies, and Politics in America's Vitamin and Herbal Supplement Industry" is an angry expose of the $21 billion supplements industry.
BusinessWeek January 8, 2007 John Carey	A Little Blue Pill For Women? A German drugmaker has stumbled upon a substance that increases female arousal.
<Older 3371-3380 Newer> Return to current articles.